References
- Rodríguez-Macías G, Martínez-Laperche C, Gayoso J, et al. Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia. Hum Pathol. 2013;44(8):1696–1699.
- Herold S, Kuhn M, Bonin M, et al. Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia 2017;31:1637–1640.
- Chonabayashi K, Kondo T, Yamamoto K, et al. Successful use of second cord blood transplantation to achieve long-term remission in cord blood donor cell-derived AML harboring a FLT3-ITD and an NPM1 mutation. Bone Marrow Transplant. 2012;47(9):1252–1253.
- Hahn CN, Ross DM, Feng J, et al. A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia. 2015;29(10):2101–2104.
- Engel N, Rovo A, Badoglio M, et al. European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. Leukemia. 2019;33(2):508–517.
- Kayser S, Döhner K, Rgen Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Clin Trial. 2011;117(7):2137–2145.
- Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011;17(6):771–789.
- Jacobs JFM, Brons PP, Simons A, et al. Therapy-related, donor-derived AML responding to a second allogeneic BMT. Bone Marrow Transplant. 2007;40(5):499–500.
- Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668–1679.